BJMO - volume 12, issue 4, august 2018
B. Neyns MD, PhD, G. Awada MD, J. K. Schwarze
This article will summarize the key data in the field of immunotherapy presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
Read moreBJMO - volume 12, issue 4, august 2018
Tom Feys MBA, MSc
The melanoma highlights from ASCO 2018 include data on the surgical management of sentinel lymph node (SLN) positive melanoma, updated results from the Checkmate 238 study evaluating adjuvant nivolumab or ipilimumab for resected stage III and IV melanoma, the overall survival (OS) data of the COLUMBUS trial assessing the combination of the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib in the treatment of unresectable BRAF-mutant melanoma and two studies evaluating immunotherapy for unresectable Merkel cell carcinoma. For a more complete overview of melanoma data presented at ASCO 2018 please refer to the official congress website (www.am.asco.org).
Read moreBJMO - volume 12, issue 3, may 2018
W. Lybaert MD, I. Dero MD, M. Peeters MD, PhD
With the background of the famous Golden Gate Bridge and Alcatraz, the annual Gastrointestinal Cancers Symposium was held from 18–20 January 2018 in the Moscone Congress Center in San Francisco, California. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2018:12(3):133–141)
Read moreBJMO - volume 12, issue 3, may 2018
L. Decoster MD, PhD, H. Rouvière MD, C. Kenis RN, PhD
The 2017 annual conference of the International Society of Geriatric Oncology took place in Warsaw, Poland from November 9–11th. More than 300 delegates from 42 countries with a special interest in the care for older patients with cancer attended this conference. The meeting provided an overview of current advances in geriatric oncology.
(BELG J MED ONCOL 2018:12(3):142–144)
Read moreBJMO - volume 12, issue 10, march 2018
M. Albersen MD, PhD, MD , PhD
It has become of yearly tradition of BMUC to put a tumor type in the spotlight that is often overlooked at (inter)national symposia. This year, Prof. Maarten Albersen gave an overview of the current treatment landscape of penile cancer.
BJMO - volume 12, issue 10, march 2018
No authors
2018 Marked the 5th edition of the Belgian Multidisciplinary Meeting on Urological Cancers (BMUC). This meeting is a collaboration between the BSMO, BVU/SBU, and BVRO/ABRO and took place on 9 and 10 March 2018. We invited Prof. Sylvie Rottey (BMUC President) to share her thoughts on the achievements of BMUC and of the future plans with the organization.
Read moreBJMO - volume 12, issue 10, march 2018
A. de la Taille
Data regarding the natural history of prostate cancer (PCa) disease confirm the clinical insignificance of low-grade prostate cancer, which is associated with scant or no metastatic dissemination. Active surveillance (AS) is a conservative management approach, conducted for patients with “low-” or “favorable-risk” disease, which avoids long-term adverse effects on the patient’s quality of life. In a lecture during BMUC 2018, Prof. de la Taille explained why he thinks that AS is an option that we need to consider and why we should discuss this with the patient before the biopsy is taken.
Top
